The National Cancer Institute (NCI), through the National Institutes of Health (NIH), solicits grant applications proposing exploratory research projects to evaluate the performance of emerging molecular analysis technologies and develop applications for an appropriate cancer-relevant biological system. These systems may cover cancer-relevant molecular analyses in vitro, in situ, and/or in vivo.
The thrust of effort in the projects proposed in response to this FOA must be on emerging technology application rather than on technology development. “Emerging technology” is one that has passed the initial developmental stage and shows promise but has not been evaluated/developed in the context of the proposed application and has not been commercialized. Responsive “technologies” encompass relevant methods, techniques, tools, instrumentation, and devices (but not software or informatics solutions).
This Funding Opportunity Announcement (FOA) is part of the broader NCI-sponsored program Innovative Molecular Analysis Technologies (IMAT). Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate notice in the NIH Guide for Grants and Contracts provides a brief cross-comparison and links to all the IMAT FOAs. See
NOT-CA-08-003.
